| Title |
Does fingolimod in multiple sclerosis patients cause macular edema?
|
|---|---|
| Published in |
Journal of Neurology, January 2012
|
| DOI | 10.1007/s00415-011-6367-4 |
| Pubmed ID | |
| Authors |
Kiran Turaka, Joseph Shepard Bryan |
| Abstract |
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system and is the common cause of optic neuritis. Fingolimod, an immunosuppressive agent, is used in MS to prevent acute exacerbations. We report a case of relapsing-remitting MS treated with fingolimod. The patient presented with an acute decrease in vision in the left eye. Eye examination showed clinical macular edema (ME) in the left eye, which was confirmed on fluorescein angiogram and optical coherence tomography (OCT). After discontinuation of fingolimod and treatment with topical corticosteroid medication, there was complete resolution of the ME. The ME as a side-effect of fingolimod is reversible after discontinuing, which was seen on OCT. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Costa Rica | 1 | 50% |
| Austria | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 4% |
| Portugal | 1 | 2% |
| Unknown | 48 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 10 | 20% |
| Researcher | 6 | 12% |
| Student > Ph. D. Student | 5 | 10% |
| Professor > Associate Professor | 5 | 10% |
| Student > Postgraduate | 4 | 8% |
| Other | 11 | 22% |
| Unknown | 10 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 51% |
| Neuroscience | 5 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Agricultural and Biological Sciences | 2 | 4% |
| Unspecified | 1 | 2% |
| Other | 3 | 6% |
| Unknown | 12 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 May 2012.
All research outputs
#15,528,325
of 23,885,338 outputs
Outputs from Journal of Neurology
#3,261
of 4,686 outputs
Outputs of similar age
#162,927
of 249,056 outputs
Outputs of similar age from Journal of Neurology
#26
of 45 outputs
Altmetric has tracked 23,885,338 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,686 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 249,056 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.